卡托普利联合阿托伐他汀治疗早期糖尿病肾病疗效观察

Clinical effective observation of captopril combined with atorvastatin in treating early diabetic nephropathy

目的观察卡托普利联合阿托伐他汀治疗早期糖尿病肾病(diabetic nephropathy,DN)的疗效。方法将86例患者随机分为研究组和对照组,每组各43例。研究组口服卡托普利,每次12.5 mg,每日3次,同时口服阿托伐他汀每天20 mg;对照组单用卡托普利,每次12.5 mg,每日3次,两组疗程均为12周。治疗前后分别测定血脂、尿微量白蛋白(mALB)、血肌酐(Scr)、C反应蛋白(CRP)、血尿素氮(BUN)等指标,并观察药物不良反应。结果治疗后研究组血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白-胆固醇(LDL-C)、高密度脂蛋白-胆固醇(HDL-C)]低于治疗前,且差异有统计学意义(P<0.05)。治疗后两组尿mALB、Scr、CRP、BUN等指标均低于治疗前,且研究组与对照组比较差异有统计学意义(P<0.05)。结论卡托普利联合阿托伐他汀治疗早期DN比单用卡托普利更有效,且不良反应未见明显增加。

Objective To explore the effects of captopril combined with atorvastatin in the treatment of early diabetic nephropathy （DN）. Methods 86 patients were randomly divided into the study group and the control group,43 cases in each group. The study group was administered with eaptopril 12.5 mg,3 times a day and atorvastatin 20 rag/d, 3 times a day and the control group only treated with captopril 12.5 rag, 3 times a day for 12 weeks. Serum lipid, urine mieroalbumin （mALB）, creatinine （Ser）, C-reactive protein （CRP） and blood urea nitrogen （BUN） were determined before and after 12-week treatment in two groups, and the drug adverse reactions were observed. Results After treatment,serum lipids （TC ,TG,LDL-C,HDL-C） in the study group were lower than those before treatment, there was statistical difference （P〈0.05）. The level of MALB, Scr, CRP and BUN in two groups are lower than that before treatment with statistical difference between them （P〈0.05）. The indexes of mALB, Ser, CRP and BUN after treatment in the two groups were lower than those before treatment, but comparing the study group and the control group showed statistical difference （P〈0.05）. Conclusion Captopril combined with atovastatin is more effective than single captopril without increasing adverse reactions to treat early DN.